NCT04924166View on ClinicalTrials.gov

PTSD Prevention Using Oral Hydrocortisone

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
PTSDAcute Stress DisorderTrauma-related Stressor
Interventions
DRUG

Placebo

Inactive dose of capsules that appear identical to active dose

DRUG

Hydrocortisone

Hydrocortisone 180 mg in capsule form

Trial Locations (3)

10025

Mount Sinai Morningside Emergency Department, New York

10029

Icahn School of Medicine at Mount Sinai, New York

Unknown

The Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
collaborator

James J. Peters Veterans Affairs Medical Center

FED

collaborator

The Chaim Sheba Medical Center

OTHER

lead

Rachel Yehuda

OTHER